
Claims

1. Use of a combination comprising dexamethasone and a compound of formula I or a pharmaceutically acceptable salt thereof:



I

in the manufacture of a medicament for the treatment of cancer.

2. The use according to claim 1, wherein the pharmaceutically acceptable salt of the compound of formula I is the hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate or acetate salt.

3. The use according to any one of claims 1 to 2, wherein the molar ratio of dexamethasone to compound of formula I or a pharmaceutically acceptable salt thereof in said combination is from 1:500 to 500:1.

4. The use according to any preceding claim, wherein said cancer is selected from a hematologic cancer and breast cancer.

5. The use of according to claim 4, wherein said hematologic cancer is selected from multiple myeloma, lymphoma and leukemia; or wherein said breast cancer is a triple negative breast cancer.


6. The use according to any preceding claim wherein said cancer is relapsed and/or refractory.

7. The use according to any preceding claim, wherein dexamethasone and the compound of formula I or a pharmaceutically acceptable salt thereof are to be administered concurrently, sequentially or separately.

8. The use according to any preceding claim, wherein dexamethasone is to be administered at a dosage range of from 0.1 to 1 mg/kg body weight patient.

9. The use according to claim 8, wherein dexamethasone is to be administered at a dosage range of from 0.3 to 0.5 mg/kg body weight patient.


10. A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and a combination comprising dexamethasone and a compound of formula I or a pharmaceutically acceptable salt thereof:



I

11. A kit comprising a pharmaceutical composition according to claim 10, and optionally, instructions for treating a patient.


12. Use of a compound of formula I or a pharmaceutically acceptable salt thereof:



I,

in the manufacture of a medicament for the treatment of cancer, wherein the compound of formula I or a pharmaceutically acceptable salt thereof is to be administered in combination with dexamethasone.

13. Use of dexamethasone in the manufacture of a medicament for the treatment of cancer, wherein a proteasome inhibitor is to be administered in combination with a compound of formula I or a pharmaceutically acceptable salt thereof:



I.